Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Savelieva, Katerina V ^a   Zhao, Shulei ^a   Pogorelov, Vladimir M ^a   Rajan, Indrani ^a   Yang, Qi ^a   Cullinan, Emily ^a,b   Lanthorn, Thomas H ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ISOENZYME; OXYGENASE; SEROTONIN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG; ISOPROTEIN; TPH1 PROTEIN, MOUSE; TPH2 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; MALE; MOLECULAR EVOLUTION; MOOD DISORDER; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTION; PROTEIN DEPLETION; VALIDATION STUDY; ANIMAL; BIOSYNTHESIS; GENETICS; MOUSE MUTANT; PHYSIOLOGY; TISSUE DISTRIBUTION;

INVERTEBRATA; MUS; VERTEBRATA;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; GENE EXPRESSION; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PHENOTYPE; PROTEIN ISOFORMS; SEROTONIN; TISSUE DISTRIBUTION; TRYPTOPHAN HYDROXYLASE;

EID: 54849404294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003301     Document Type: Article

References (52)

1. Bonasera SJ, Tecott LH (2000) Mouse models of serotonin receptor function: toward a genetic dissection of serotonin systems. Pharmacol Ther 88: 133-142.
2. Buhot MC (1997) Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7: 243-254.
3. Ericsson M, Poston WS 2nd, Foreyt JP (1996) Common biological pathways in eating disorders and obesity. Addict Behav 21: 733-743.
4. Goodman WK (1999) Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 60 Suppl 18: 27-32.
5. Julius D (1998) Serotonin receptor knockouts: a moody subject. Proc Natl Acad Sci USA 95: 15153-15154.
6. Mann JJ (1999) Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21: 99S-105S.
7. Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3 Suppl 2: S25-34.
8. Cote F, Fligny C, Bayard E, Launay JM, Gershon MD, et al. (2007) Maternal serotonin is crucial for murine embryonic development. Proc Natl Acad Sci USA 104: 329-334.
9. Coon H, Dunn D, Lainhart J, Miller J, Hamil C, et al. (2005) Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). Am J Med Genet B Neuropsychiatr Genet 135: 42-46.
10. Sheehan K, Lowe N, Kirley A, Mullins C, Fitzgerald M, et al. (2005) Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 10: 944-949.
11. Delorme R, Durand CM, Betancur C, Wagner M, Ruhrmann S, et al. (2006) No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. Biol Psychiatry 60: 202-203.
12. Haavik J, Blau N, Thony B (2008) Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 29: 891-902.
13. McKinney J, Johansson S, Halmoy A, Dramsdahl M, Winge I, et al. (2008) A loss-of-function mutation in tryptophan hydroxylase 2 segregating with attention-deficit/hyperactivity disorder. Mol Psychiatry 13: 365-367.
14. Sheehan K, Hawi Z, Gill M, Kent L (2007) No association between TPH2 gene polymorphisms and ADHD in a UK sample. Neurosci Lett 412: 105-107.
15. Ballenger JC (1999) Current treatments of the anxiety disorders in adults. Biol Psychiatry 46: 1579-1594.
16. Dodick DW, Sandrini G, Williams P (2007) Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21: 73-82.
17. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, et al. (2003) Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413-420.
18. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, et al. (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299: 76.
19. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, et al. (2003) Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA 100: 13525-13530.
20. Walther DJ, Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66: 1673-1680.
21. Wattler S, Kelly M, Nehls M (1999) Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26: 1150-1156, 1158, 1160.
22. Sambrook J, Fritsch E, Maniatis T (1989) Molecular Cloning: A Laboratory Manual. New York Cold Spring Harbor Laboratory Press.
23. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, et al. (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913-924.
24. Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29: 547-569.
25. Drugan RC, Skolnick P, Paul SM, Crawley JN (1989) A pretest procedure reliably predicts performance in two animal models of inescapable stress. Pharmacol Biochem Behav 33: 649-654.
26. Pogorelov VM, Baker KB, Malbari MM, Lanthorn TH, Savelieva KV (2008) A Standardized Behavioral Test Battery to Identify and Validate Targets for Neuropsychiatric Diseases and Pain. In: Kalueff A, LaPorte J, eds. Experimental models in neurobehavioral research. New York: Nova Science, in press.
27. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, et al. (2008) Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325: 47-55.
28. Veenstra-VanderWeele J, Cook EH Jr (2003) Knockout mouse points to second form of tryptophan hydroxylase. Mol Interv 3: 72-75, 50.
29. Li X, Morrow D, Witkin JM (2006) Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78: 1933-1939.
30. Nicolas LB, Kolb Y, Prinssen EP (2006) A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 547: 106-115.
31. Gutknecht L, Waider J, Kraft S, Kriegebaum C, Holtmann B, et al. (2008) Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice. J Neural Transm 115: 1127-1132.
32. Renson J, Weissbach H, Udenfriend S (1962) Hydroxylation of tryptophan by phenylalanine hydroxylase. J Biol Chem 237: 2261-2264.
33. Holmes A, Yang RJ, Murphy DL, Crawley JN (2002) Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27: 914-923.
34. Zhao S, Edwards J, Carroll J, Wiedholz L, Millstein RA, et al. (2006) Insertion mutation at the C-terminus of the serotonin transporter disrupts brain serotonin function and emotion-related behaviors in mice. Neuroscience 140: 321-334.
35. Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, et al. (2004) S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther 309: 936-950.
36. Kobayashi T, Hayashi E, Shimamura M, Kinoshita M, Murphy NP (2008) Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 197: 567-580.
37. Londei T, Valentini AM, Leone VG (1998) Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 94: 249-254.
38. Bai F, Li X, Clay M, Lindstrom T, Skolnick P (2001) Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 70: 187-192.
39. Bourin M, Chenu F, Ripoll N, David DJ (2005) A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 164: 266-269.
40. Renard CE, Dailly E, David DJ, Hascoet M, Bourin M (2003) Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 17: 449-455.
41. Yadid G, Overstreet DH, Zangen A (2001) Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression. Brain Res 896: 43-47.
42. Lira A, Zhou M, Castanon N, Ansorge MS, Gordon JA, et al. (2003) Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 54: 960-971.
43. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, et al. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105: 1333-1338.
44. Sommer C (2006) Is serotonin hyperalgesic or analgesic? Curr Pain Headache Rep 10: 101-106.
45. Wallace JM (2007) Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep 11: 208-214.
46. Leo RJ, Brooks VL (2006) Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 7: 637-642.
47. Begovic A, Zulic I, Becic F (2004) Testing of analgesic effect of fluoxetine. Bosn J Basic Med Sci 4: 79-81.
48. Singh VP, Jain NK, Kulkarni SK (2001) On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 915: 218-226.
49. Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16: 233-240.
50. Kobayashi K, Morita S, Sawada H, Mizuguchi T, Yamada K, et al. (1995) Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem 270: 27235-27243.
51. Zhou QY, Quaife CJ, Palmiter RD (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374: 640-643.
52. Serretti A, Benedetti F, Zanardi R, Smeraldi E (2005) The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 29: 1074-1084.